Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system

AIM: The aim of this study was to identify potential safety concerns associated with Sacituzumab Govitecan (SG), an antibody-drug conjugate targeting trophoblastic cell-surface antigen-2, by analyzing real-world safety data from the largest publicly available worldwide pharmacovigilance database. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Gui, Xiujuan, Zhao, Jianli, Ding, Linxiaoxiao, Chai, Jie, Lai, Hongna, Cai, Yangyang, Luo, Simin, Zeng, Yinduo, Wu, Wenjing, Chen, Haizhu, Yao, Herui, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587566/
https://www.ncbi.nlm.nih.gov/pubmed/37869095
http://dx.doi.org/10.3389/fonc.2023.1276976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587566/
https://www.ncbi.nlm.nih.gov/pubmed/37869095
http://dx.doi.org/10.3389/fonc.2023.1276976

Ejemplares similares